EICHOR
● Active Not Recruiting
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
Condition: HIV-1 Infection · Sponsor: Merck Sharp & Dohme LLC
About this study
This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL \[MK-8591A\]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (131)
| Pueblo Family Physicians ( Site 5674) | Phoenix, Arizona, United States | — |
| Pacific Oaks Medical Group ( Site 5681) | Beverly Hills, California, United States | — |
| Ruane Clinical Research Group, Inc ( Site 5658) | Los Angeles, California, United States | — |
| Vivent Health ( Site 5694) | Denver, Colorado, United States | — |
| Washington Health Institute ( Site 5689) | Washington D.C., District of Columbia, United States | — |
| Midway Immunology and Research Center ( Site 5657) | Ft. Pierce, Florida, United States | — |
| AHF The Kinder Medical Group ( Site 5672) | Miami, Florida, United States | — |
| AHF South Beach ( Site 5663) | Miami Beach, Florida, United States | — |
| Orlando Immunology Center ( Site 5654) | Orlando, Florida, United States | — |
| CAN Community Health - Sarasota ( Site 5668) | Sarasota, Florida, United States | — |
| Triple O Research Institute, P.A ( Site 5666) | West Palm Beach, Florida, United States | — |
| Emory University and Grady Health System-Medicine ( Site 5690) | Atlanta, Georgia, United States | — |
+ 119 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05705349